Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial

BACKGROUND: Mexico has one of the highest prevalence rates of obesity worldwide. New pharmacological strategies that focus on people with class III obesity are required. Metformin and dapagliflozin are two drugs approved for the treatment of diabetes. Beyond its effects on glucose, metformin has bee...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Trials
Autori principali: Ferreira-Hermosillo, Aldo, Molina-Ayala, Mario Antonio, Molina-Guerrero, Diana, Garrido-Mendoza, Ana Pamela, Ramírez-Rentería, Claudia, Mendoza-Zubieta, Victoria, Espinosa, Etual, Mercado, Moisés
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Study Protocol
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7023779/
https://ncbi.nlm.nih.gov/pubmed/32059692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-020-4121-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi